Zura Bio LTD Schedule 13G passive stakes

Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have jointly filed a Schedule 13G, reporting beneficial ownership of 4,215,930 Class A Ordinary Shares of Zura Bio Limited, representing 4.44% of the class.

Suvretta Capital Management and Aaron Cowen report a 9.9% beneficial ownership stake in Zura Bio Limited via Schedule 13G filing.

JPMorgan Chase & Co. has filed a Schedule 13G, reporting beneficial ownership of 4.7% of Zura Bio Ltd.'s Class A Ordinary Shares as of April 30, 2026.

Suvretta Capital Management, Averill Master Fund, and Aaron Cowen report continued significant beneficial ownership in Zura Bio Limited's Class A Ordinary Shares.

Athanor Capital and UGS Capital LLC jointly reported a 15.7% beneficial ownership stake in Zura Bio Limited's Class A Ordinary Shares.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, reported a 5.87% beneficial ownership stake in Zura Bio Ltd's Class A Ordinary Shares.

Deep Track Capital, LP and affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 0.40% in Zura Bio Ltd.'s Class A Ordinary Shares.

Venrock Healthcare Capital Partners and affiliated entities reported a 9.99% beneficial ownership stake in Zura Bio Limited's Class A Ordinary Shares as of June 30, 2025.

Deep Track Capital and affiliates have disclosed a 7.13% beneficial ownership stake in ZURA Bio Ltd, totaling 4,616,514 Class A Ordinary Shares.

JPMorgan Chase & Co. has disclosed a 7.5% beneficial ownership stake in Zura Bio Limited's Class A Ordinary Shares, as reported in a Schedule 13G filing.

A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, confirming their collective beneficial ownership of 9.9% of Zura Bio Limited's Class A Ordinary Shares as of March 31, 2025.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, have jointly disclosed a beneficial ownership of 5.12% in Zura Bio Ltd's Class A Ordinary Shares.

ADAR1 Capital Management, along with its general partner and manager Daniel Schneeberger, has filed an amended Schedule 13G reporting a combined beneficial ownership of 3.18% in ZURA BIO LIMITED's Class A Ordinary Shares as of December 31, 2024.

RA Capital Management and its affiliates have filed an amended Schedule 13G, reporting a 4.9% beneficial ownership stake in Zura Bio Limited's Class A Ordinary Shares as of December 31, 2024.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, have jointly reported a beneficial ownership of 4.86% of ZURA BIO LIMITED's Class A Ordinary Shares as of December 31, 2024.

Pfizer Inc. has reported a 4.6% beneficial ownership stake in Zura Bio Limited's Class A Ordinary Shares as of December 31, 2024, according to a recent SEC Schedule 13G filing.